1
|
Novaes GM, Lima C, Longo C, Machado PH, Silva TP, Olberg GGDO, Módolo DG, Pereira MCL, Santos TG, Zatz M, Lagares D, de Franco M, Ho PL, Bulstrode H, Okamoto OK, Kaid C. Genetically modified ZIKA virus as a microRNA-sensitive oncolytic virus against central nervous system tumors. Mol Ther 2024; 32:440-456. [PMID: 38213031 PMCID: PMC10861990 DOI: 10.1016/j.ymthe.2024.01.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 10/09/2023] [Accepted: 01/05/2024] [Indexed: 01/13/2024] Open
Abstract
Here we introduce a first-in-class microRNA-sensitive oncolytic Zika virus (ZIKV) for virotherapy application against central nervous system (CNS) tumors. The described methodology produced two synthetic modified ZIKV strains that are safe in normal cells, including neural stem cells, while preserving brain tropism and oncolytic effects in tumor cells. The microRNA-sensitive ZIKV introduces genetic modifications in two different virus sites: first, in the established 3'UTR region, and secondly, in the ZIKV protein coding sequence, demonstrating for the first time that the miRNA inhibition systems can be functional outside the UTR RNA sites. The total tumor remission in mice bearing human CNS tumors, including metastatic tumor growth, after intraventricular and systemic modified ZIKV administration, confirms the promise of this virotherapy as a novel agent against brain tumors-highly deadly diseases in urgent need of effective advanced therapies.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Tiago Goss Santos
- International Research Center/CIPE, A.C. Camargo Cancer Center, Sao Paulo 01508-010, Brazil
| | - Mayana Zatz
- Human Genome and Stem Cell Research Center, Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of Sao Paulo, Sao Paulo 05508-900, Brazil
| | - David Lagares
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
| | | | - Paulo Lee Ho
- Butantan Institute, BioIndustrial Center, Sao Paulo 05503-900, Brazil
| | - Harry Bulstrode
- Wellcome-Medical Research Council Cambridge Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge CB2 0AW, UK
| | - Oswaldo Keith Okamoto
- Human Genome and Stem Cell Research Center, Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of Sao Paulo, Sao Paulo 05508-900, Brazil
| | | |
Collapse
|
2
|
Momin SMB, Aquilina K, Bulstrode H, Taira T, Kalia S, Natalwala A. MRI-Guided Focused Ultrasound for the Treatment of Dystonia: A Narrative Review. Cureus 2024; 16:e54284. [PMID: 38500932 PMCID: PMC10945285 DOI: 10.7759/cureus.54284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/16/2024] [Indexed: 03/20/2024] Open
Abstract
Contemporary surgical management of dystonia includes neuromodulation via deep brain stimulation (DBS) or ablative techniques such as radiofrequency (RF) ablation. MRI-guided focused ultrasound (MRgFUS) is an emerging modality that uses high-intensity ultrasound to precisely ablate targets in the brain; this is incisionless, potentially avoiding the surgical risks of a burr hole and transcortical tract to reach the anatomical target. There is some evidence of efficacy in essential tremor and Parkinson's disease (PD), but, to date, there is no study aggregating the evidence of MRgFUS in dystonia. In this narrative review, we searched Medline, Embase, CINAHL, EBSCO, and ClinicalTrials.gov for primary studies and clinical trials on MRgFUS in the treatment of dystonia. Data were analyzed concerning dystonia phenotype, reported outcomes, and complications. PD-related dystonia was also included within the scope of the review. Using our search criteria, six articles on the use of MRgFUS in adult dystonia and three articles on the use of FUS in dystonia in PD were included. Four trials on the use of FUS in dystonia were also found on ClinicalTrials.gov, one of which was completed in December 2013. All included studies showed evidence of symptomatic improvement, mostly in focal hand dystonia; improvements were also found in dystonia-associated tremor, cervicobrachial dystonia, and dystonia-associated chronic neuropathic pain as well as PD-related dystonia. Reported complications included transient neurological deficits and persistent arm pain in one study. However, the evidence is limited to level-4 case series at present. MRgFUS is an emerging modality that appears to be safe and effective, particularly in focal hand dystonia, without major adverse effects. However, the quality of evidence is low at present, and long-term outcomes are unknown. High-quality prospective studies comparing MRgFUS to other surgical techniques will be useful in determining its role in the management of dystonia.
Collapse
Affiliation(s)
- Sheikh Muktadir Bin Momin
- Institute of Inflammation & Ageing, University of Birmingham, Birmingham, GBR
- Department of Neurosurgery, Queen Elizabeth Hospital, Birmingham, GBR
| | - Kristian Aquilina
- Department of Paediatric Neurosurgery, Great Ormond Street Hospital, London, GBR
| | - Harry Bulstrode
- Department of Neurosurgery, Wellcome-MRC Cambridge Stem Cell Institute, Addenbrooke's Hospital, Cambridge, GBR
| | - Takaomi Taira
- Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, JPN
| | - Suneil Kalia
- Division of Neurosurgery, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, CAN
| | - Ammar Natalwala
- Victor Horsley Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, London, GBR
- Department of Neuromuscular Diseases, Institute of Neurology, University College London, London, GBR
| |
Collapse
|
3
|
Maheshwari S, Akram H, Bulstrode H, Kalia SK, Morizane A, Takahashi J, Natalwala A. Dopaminergic Cell Replacement for Parkinson's Disease: Addressing the Intracranial Delivery Hurdle. J Parkinsons Dis 2024; 14:415-435. [PMID: 38457149 DOI: 10.3233/jpd-230328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/09/2024]
Abstract
Parkinson's disease (PD) is an increasingly prevalent neurological disorder, affecting more than 8.5 million individuals worldwide. α-Synucleinopathy in PD is considered to cause dopaminergic neuronal loss in the substantia nigra, resulting in characteristic motor dysfunction that is the target for current medical and surgical therapies. Standard treatment for PD has remained unchanged for several decades and does not alter disease progression. Furthermore, symptomatic therapies for PD are limited by issues surrounding long-term efficacy and side effects. Cell replacement therapy (CRT) presents an alternative approach that has the potential to restore striatal dopaminergic input and ameliorate debilitating motor symptoms in PD. Despite promising pre-clinical data, CRT has demonstrated mixed success clinically. Recent advances in graft biology have renewed interest in the field, resulting in several worldwide ongoing clinical trials. However, factors surrounding the effective neurosurgical delivery of cell grafts have remained under-studied, despite their significant potential to influence therapeutic outcomes. Here, we focus on the key neurosurgical factors to consider for the clinical translation of CRT. We review the instruments that have been used for cell graft delivery, highlighting current features and limitations, while discussing how future devices could address these challenges. Finally, we review other novel developments that may enhance graft accessibility, delivery, and efficacy. Challenges surrounding neurosurgical delivery may critically contribute to the success of CRT, so it is crucial that we address these issues to ensure that CRT does not falter at the final hurdle.
Collapse
Affiliation(s)
- Saumya Maheshwari
- The Medical School, University of Edinburgh, Edinburgh BioQuarter, UK
| | - Harith Akram
- Unit of Functional Neurosurgery, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Trust, London, UK
| | - Harry Bulstrode
- Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK
- Department of Clinical Neurosciences, Division of Academic Neurosurgery, University of Cambridge, Cambridge, UK
| | - Suneil K Kalia
- Division of Neurosurgery, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Canada
| | - Asuka Morizane
- Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan
- Department of Regenerative Medicine, Center for Clinical Research and Innovation, Kobe City Medical Center General Hospital, Hyogo, Japan
| | - Jun Takahashi
- Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan
- Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Ammar Natalwala
- Unit of Functional Neurosurgery, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Trust, London, UK
- Department for Neuromuscular Diseases, Institute of Neurology, University College London, London, UK
| |
Collapse
|
4
|
Robertson FL, O'Duibhir E, Gangoso E, Bressan RB, Bulstrode H, Marqués-Torrejón MÁ, Ferguson KM, Blin C, Grant V, Alfazema N, Morrison GM, Pollard SM. Elevated FOXG1 in glioblastoma stem cells cooperates with Wnt/β-catenin to induce exit from quiescence. Cell Rep 2023; 42:112561. [PMID: 37243590 DOI: 10.1016/j.celrep.2023.112561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2022] [Revised: 09/30/2022] [Accepted: 05/08/2023] [Indexed: 05/29/2023] Open
Abstract
Glioblastoma (GBM) stem cells (GSCs) display phenotypic and molecular features reminiscent of normal neural stem cells and exhibit a spectrum of cell cycle states (dormant, quiescent, proliferative). However, mechanisms controlling the transition from quiescence to proliferation in both neural stem cells (NSCs) and GSCs are poorly understood. Elevated expression of the forebrain transcription factor FOXG1 is often observed in GBMs. Here, using small-molecule modulators and genetic perturbations, we identify a synergistic interaction between FOXG1 and Wnt/β-catenin signaling. Increased FOXG1 enhances Wnt-driven transcriptional targets, enabling highly efficient cell cycle re-entry from quiescence; however, neither FOXG1 nor Wnt is essential in rapidly proliferating cells. We demonstrate that FOXG1 overexpression supports gliomagenesis in vivo and that additional β-catenin induction drives accelerated tumor growth. These data indicate that elevated FOXG1 cooperates with Wnt signaling to support the transition from quiescence to proliferation in GSCs.
Collapse
Affiliation(s)
- Faye L Robertson
- Centre for Regenerative Medicine & Edinburgh Cancer Research UK Centre, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, UK
| | - Eoghan O'Duibhir
- Centre for Regenerative Medicine & Edinburgh Cancer Research UK Centre, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, UK
| | - Ester Gangoso
- Centre for Regenerative Medicine & Edinburgh Cancer Research UK Centre, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, UK
| | - Raul Bardini Bressan
- Centre for Regenerative Medicine & Edinburgh Cancer Research UK Centre, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, UK
| | - Harry Bulstrode
- Centre for Regenerative Medicine & Edinburgh Cancer Research UK Centre, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, UK
| | - Maria-Ángeles Marqués-Torrejón
- Centre for Regenerative Medicine & Edinburgh Cancer Research UK Centre, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, UK
| | - Kirsty M Ferguson
- Centre for Regenerative Medicine & Edinburgh Cancer Research UK Centre, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, UK
| | - Carla Blin
- Centre for Regenerative Medicine & Edinburgh Cancer Research UK Centre, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, UK
| | - Vivien Grant
- Centre for Regenerative Medicine & Edinburgh Cancer Research UK Centre, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, UK
| | - Neza Alfazema
- Centre for Regenerative Medicine & Edinburgh Cancer Research UK Centre, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, UK
| | - Gillian M Morrison
- Centre for Regenerative Medicine & Edinburgh Cancer Research UK Centre, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, UK
| | - Steven M Pollard
- Centre for Regenerative Medicine & Edinburgh Cancer Research UK Centre, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, UK.
| |
Collapse
|
5
|
Bulstrode H, Girdler GC, Gracia T, Aivazidis A, Moutsopoulos I, Young AMH, Hancock J, He X, Ridley K, Xu Z, Stockley JH, Finlay J, Hallou C, Fajardo T, Fountain DM, van Dongen S, Joannides A, Morris R, Mair R, Watts C, Santarius T, Price SJ, Hutchinson PJA, Hodson EJ, Pollard SM, Mohorianu I, Barker RA, Sweeney TR, Bayraktar O, Gergely F, Rowitch DH. Myeloid cell interferon secretion restricts Zika flavivirus infection of developing and malignant human neural progenitor cells. Neuron 2022; 110:3936-3951.e10. [PMID: 36174572 PMCID: PMC7615581 DOI: 10.1016/j.neuron.2022.09.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2022] [Revised: 08/10/2022] [Accepted: 09/01/2022] [Indexed: 02/02/2023]
Abstract
Zika virus (ZIKV) can infect human developing brain (HDB) progenitors resulting in epidemic microcephaly, whereas analogous cellular tropism offers treatment potential for the adult brain cancer, glioblastoma (GBM). We compared productive ZIKV infection in HDB and GBM primary tissue explants that both contain SOX2+ neural progenitors. Strikingly, although the HDB proved uniformly vulnerable to ZIKV infection, GBM was more refractory, and this correlated with an innate immune expression signature. Indeed, GBM-derived CD11b+ microglia/macrophages were necessary and sufficient to protect progenitors against ZIKV infection in a non-cell autonomous manner. Using SOX2+ GBM cell lines, we found that CD11b+-conditioned medium containing type 1 interferon beta (IFNβ) promoted progenitor resistance to ZIKV, whereas inhibition of JAK1/2 signaling restored productive infection. Additionally, CD11b+ conditioned medium, and IFNβ treatment rendered HDB progenitor lines and explants refractory to ZIKV. These findings provide insight into neuroprotection for HDB progenitors as well as enhanced GBM oncolytic therapies.
Collapse
Affiliation(s)
- Harry Bulstrode
- Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Division of Academic Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK.
| | - Gemma C Girdler
- Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Division of Academic Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Tannia Gracia
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK
| | | | - Ilias Moutsopoulos
- Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK
| | - Adam M H Young
- Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Division of Academic Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK
| | - John Hancock
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK
| | - Xiaoling He
- Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK
| | - Katherine Ridley
- Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Department of Paediatrics, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Zhaoyang Xu
- Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Department of Paediatrics, University of Cambridge, Cambridge CB2 0QQ, UK
| | - John H Stockley
- Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Department of Paediatrics, University of Cambridge, Cambridge CB2 0QQ, UK
| | - John Finlay
- Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Department of Paediatrics, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Clement Hallou
- Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Department of Paediatrics, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Teodoro Fajardo
- Department of Virology, University of Cambridge, Cambridge CB2 0QQ, UK; Department of Virology, Royal London Hospital, Barts Health NHS Trust, London E1 2ES, UK
| | | | | | - Alexis Joannides
- Division of Academic Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Robert Morris
- Division of Academic Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Richard Mair
- Division of Academic Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Colin Watts
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2SY, UK
| | - Thomas Santarius
- Division of Academic Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Stephen J Price
- Division of Academic Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Peter J A Hutchinson
- Division of Academic Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Emma J Hodson
- Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Steven M Pollard
- Centre for Regenerative Medicine and Cancer Research UK Edinburgh Centre, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, UK
| | - Irina Mohorianu
- Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK
| | - Roger A Barker
- Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK
| | - Trevor R Sweeney
- Department of Virology, University of Cambridge, Cambridge CB2 0QQ, UK; The Pirbright Institute, Guildford, Surrey GU24 0NF, UK
| | | | - Fanni Gergely
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.
| | - David H Rowitch
- Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Wellcome Sanger Institute, Hinxton CB10 1SA, UK; Department of Paediatrics, University of Cambridge, Cambridge CB2 0QQ, UK.
| |
Collapse
|
6
|
Brandis P, Hall S, Bulstrode H, Nichols P, Hempenstall J, Amato D, Durnford A. Emergency Intraoperative Ultrasound for the Neurosurgical Trainee. World Neurosurg 2021; 153:79-83. [PMID: 34229102 DOI: 10.1016/j.wneu.2021.06.138] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Accepted: 06/28/2021] [Indexed: 11/26/2022]
Abstract
The use of intraoperative ultrasound in emergency cranial neurosurgical procedures is not well described. It may improve surgical outcomes and is useful when other neuro-navigation systems are not readily available. We provide a practical guide for neurosurgical trainees to utilize ultrasound for various emergency cranial neurosurgical procedures, including lesion localization, insertion of an external ventricular drain, and shunt revision surgery. Intraoperative ultrasound is a useful modality for urgent neurosurgical procedures.
Collapse
Affiliation(s)
- Phoebe Brandis
- Department of Neurosurgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia
| | - Samuel Hall
- Wessex Neurological Centre, University Hospital Southampton, Southampton, United Kingdom
| | - Harry Bulstrode
- Department of Clinical Neurosciences, Addenbrookes Hospital, Cambridge, United Kingdom
| | - Paul Nichols
- Department of Neurosurgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia
| | - Jonathan Hempenstall
- Wessex Neurological Centre, University Hospital Southampton, Southampton, United Kingdom
| | - Damian Amato
- Department of Neurosurgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia
| | - Andrew Durnford
- Department of Neurosurgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia; Wessex Neurological Centre, University Hospital Southampton, Southampton, United Kingdom
| |
Collapse
|
7
|
Gerigk M, Bulstrode H, Shi HH, Tönisen F, Cerutti C, Morrison G, Rowitch D, Huang YYS. On-chip perivascular niche supporting stemness of patient-derived glioma cells in a serum-free, flowable culture. Lab Chip 2021; 21:2343-2358. [PMID: 33969368 PMCID: PMC8204159 DOI: 10.1039/d1lc00271f] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Accepted: 05/03/2021] [Indexed: 05/05/2023]
Abstract
Glioblastoma multiforme (GBM) is the most common and the most aggressive type of primary brain malignancy. Glioblastoma stem-like cells (GSCs) can migrate in vascular niches within or away from the tumour mass, increasing tumour resistance to treatments and contributing to relapses. To study individual GSC migration and their interactions with the perivasculature of the tumour microenvironment, there is a need to develop a human organotypic in vitro model. Herein, we demonstrated a perivascular niche-on-a-chip, in a serum-free condition with gravity-driven flow, that supported the stemness of patient-derived GSCs and foetal neural stem cells grown in a three-dimensional environment (3D). Endothelial cells from three organ origins, (i) human brain microvascular endothelial cells (hCMEC/D3), (ii) human umbilical vein endothelial cells (HUVECs) and, (iii) human lung microvascular endothelial cells (HMVEC-L) formed rounded microvessels within the extracellular-matrix integrated microfluidic chip. By optimising cell extraction protocols, systematic studies were performed to evaluate the effects of serum-free media, 3D cell cultures, and the application of gravity-driven flow on the characteristics of endothelial cells and their co-culture with GSCs. Our results showed the maintenance of adherent and tight junction markers of hCMEC/D3 in the serum-free culture and that gravity-driven flow was essential to support adequate viability of both the microvessel and the GSCs in co-culture (>80% viability at day 3). Endpoint biological assays showed upregulation of neovascularization-related genes (e.g., angiopoietins, vascular endothelial growth factor receptors) in endothelial cells co-cultured with GSCs in contrast to the neural stem cell reference that showed insignificant changes. The on-chip platform further permitted live-cell imaging of GSC - microvessel interaction, enabling quantitative analysis of GSC polarization and migration. Overall, our comparative genotypic (i.e. qPCR) and phenotypic (i.e. vessel permeability and GSC migration) studies showed that organotypic (brain cancer cells-brain endothelial microvessel) interactions differed from those within non-tissue specific vascular niches of human origin. The development and optimization of this on-chip perivascular niche, in a serum-free flowable culture, could provide the next level of complexity of an in vitro system to study the influence of glioma stem cells on brain endothelium.
Collapse
Affiliation(s)
- Magda Gerigk
- Department of Engineering, University of Cambridge, UK. and The Nanoscience Centre, University of Cambridge, UK
| | - Harry Bulstrode
- Department of Clinical Neuroscience, University of Cambridge, UK
| | - HaoTian Harvey Shi
- Department of Mechanical & Industrial Engineering, University of Toronto, Canada and Department of Engineering, University of Cambridge, UK.
| | - Felix Tönisen
- Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Radboudumc, Netherlands and Department of Engineering, University of Cambridge, UK.
| | - Camilla Cerutti
- Randall Centre of Cell & Molecular Biophysics, King's College London, UK
| | | | - David Rowitch
- Department of Paediatrics, University of Cambridge, UK
| | - Yan Yan Shery Huang
- Department of Engineering, University of Cambridge, UK. and The Nanoscience Centre, University of Cambridge, UK
| |
Collapse
|
8
|
Tabet A, Gebhart T, Wu G, Readman C, Pierson Smela M, Rana VK, Baker C, Bulstrode H, Anikeeva P, Rowitch DH, Scherman OA. Applying support-vector machine learning algorithms toward predicting host-guest interactions with cucurbit[7]uril. Phys Chem Chem Phys 2020; 22:14976-14982. [PMID: 32588846 DOI: 10.1039/c9cp05800a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Machine learning is a valuable tool in the development of chemical technologies but its applications into supramolecular chemistry have been limited. Here, the utility of kernel-based support vector machine learning using density functional theory calculations as training data is evaluated when used to predict equilibrium binding coefficients of small molecules with cucurbit[7]uril (CB[7]). We find that utilising SVMs may confer some predictive ability. This algorithm was then used to predict the binding of drugs TAK-580 and selumetinib. The algorithm did predict strong binding for TAK-580 and poor binding for selumetinib, and these results were experimentally validated. It was discovered that the larger homologue cucurbit[8]uril (CB[8]) is partial to selumetinib, suggesting an opportunity for tunable release by introducing different concentrations of CB[7] or CB[8] into a hydrogel depot. We qualitatively demonstrated that these drugs may have utility in combination against gliomas. Finally, mass transfer simulations show CB[7] can independently tune the release of TAK-580 without affecting selumetinib. This work gives specific evidence that a machine learning approach to recognition of small molecules by macrocycles has merit and reinforces the view that machine learning may prove valuable in the development of drug delivery systems and supramolecular chemistry more broadly.
Collapse
Affiliation(s)
- Anthony Tabet
- Melville Laboratory for Polymer Synthesis, Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Patel K, Budohoski KP, Olijnyk LD, Bulstrode H, Santarius T, Kirollos RW, Trivedi RA. Infratentorial Supracerebellar Approach for Resection of Midbrain Cavernous Malformation: 3-Dimensional Operative Video. Oper Neurosurg (Hagerstown) 2020; 18:E44. [PMID: 31162594 DOI: 10.1093/ons/opz114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2018] [Accepted: 01/21/2019] [Indexed: 11/12/2022] Open
Abstract
Cavernous malformations (cavernomas) of the brain stem with recurrent hemorrhage may be amenable to microsurgical resection if they are present close to the surface. The risks of surgery need to be balanced with the natural history of the lesion and the accumulation of neurological deficits and risk to life with multiple hemorrhages. In this 3D operative video, we illustrate the technique for the resection of a dorsally located midbrain cavernous malformation. Informed consent was obtained for this procedure. The cavernoma is accessed with the use of a supracerebellar infratentorial approach. The infratentorial craniotomy and coagulation of the superior vermian veins is shown. A description is provided of the use of hemosiderin staining and the intercollicular relative "safe zone"1 as landmarks for the neurotomy. The technique of cavernoma dissection from the surrounding gliotic plane is shown and described. In this case, the patient required prolonged rehabilitation but fully recovered without residual deficit 1 yr following surgery.
Collapse
Affiliation(s)
- Krunal Patel
- Division of Neurosurgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
| | - Karol P Budohoski
- Division of Neurosurgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
| | | | - Harry Bulstrode
- Division of Neurosurgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
| | - Thomas Santarius
- Division of Neurosurgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
| | - Ramez W Kirollos
- Division of Neurosurgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
| | - Rikin A Trivedi
- Division of Neurosurgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
| |
Collapse
|
10
|
Rana VK, Tabet A, Vigil JA, Balzer CJ, Narkevicius A, Finlay J, Hallou C, Rowitch DH, Bulstrode H, Scherman OA. Cucurbit[8]uril-Derived Graphene Hydrogels. ACS Macro Lett 2019; 8:1629-1634. [PMID: 35619388 DOI: 10.1021/acsmacrolett.9b00717] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The scalable production of uniformly distributed graphene (GR)-based composite materials remains a sizable challenge. While GR-polymer nanocomposites can be manufactured at a large scale, processing limitations result in poor control over the homogeneity of hydrophobic GR sheets in the matrices. Such processes often result in difficulties controlling stability and avoiding aggregation, therefore eliminating benefits that might have otherwise arisen from the nanoscopic dimensions of GR. Here, we report an exfoliated and stabilized GR dispersion in water. Cucurbit[8]uril (CB[8])-mediated host-guest chemistry was used to obtain supramolecular hydrogels consisting of uniformly distributed GR and guest-functionalized macromolecules. The obtained GR hydrogels show superior bioelectrical properties over identical systems produced without CB[8]. Utilizing such supramolecular interactions with biologically derived macromolecules is a promising approach to stabilize graphene in water and avoid oxidative chemistry.
Collapse
Affiliation(s)
- Vijay K. Rana
- Melville Laboratory for Polymer Synthesis, Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K
| | - Anthony Tabet
- Melville Laboratory for Polymer Synthesis, Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K
- Department of Paediatrics, Addenbrooke’s Hospital, University of Cambridge, Hills Road, Cambridge CB2 0QQ, U.K
| | - Julian A. Vigil
- Melville Laboratory for Polymer Synthesis, Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K
| | - Christopher J. Balzer
- Melville Laboratory for Polymer Synthesis, Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K
| | - Aurimas Narkevicius
- Melville Laboratory for Polymer Synthesis, Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K
| | - John Finlay
- Department of Paediatrics, Addenbrooke’s Hospital, University of Cambridge, Hills Road, Cambridge CB2 0QQ, U.K
| | - Clement Hallou
- Department of Paediatrics, Addenbrooke’s Hospital, University of Cambridge, Hills Road, Cambridge CB2 0QQ, U.K
| | - David H. Rowitch
- Department of Paediatrics, Addenbrooke’s Hospital, University of Cambridge, Hills Road, Cambridge CB2 0QQ, U.K
| | - Harry Bulstrode
- Department of Paediatrics, Addenbrooke’s Hospital, University of Cambridge, Hills Road, Cambridge CB2 0QQ, U.K
| | - Oren A. Scherman
- Melville Laboratory for Polymer Synthesis, Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K
| |
Collapse
|
11
|
Girdler G, Gracia T, Fountain D, Fajardo Jr T, Finlay J, Hallou C, Pollard S, Sweeney T, Gergely F, Rowitch D, Bulstrode H. Identifying the Zika Virus Target Cell in Malignant Glioma. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz167.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
The Zika Virus epidemic of 2015–2016 was associated with striking failure of forebrain development in infants born to infected mothers, resulting in microcephaly. Studies from numerous labs subsequently confirmed a selective effect of the virus on neural stem cell survival, self-renewal and differentiation. The glioma stem cells which drive glioblastoma and other malignant gliomas depend on neural stem cell transcription programs, so that understanding Zika infection in these cells promises valuable insights into future therapy. We describe here:
1) Study of low passage patient-derived glioblastoma cell lines and normal neural stem cells (CRUK Glioma Cellular Genetics Resource) in adherent culture to address the influence of glioma subtype on infectability
2) Application of genetically modified mCherry reporter Zika Virus strains to address the Zika target cell in glioblastoma.
3) Development of a cerebral organoid model to interrogate the differential effects of the virus on tumour cells and surrounding normal brain.
4) Demonstration of Zika infection on primary patient derived tissue in slice culture format
Using these tools we find that Zika targets a common stem cell population across tumour subtypes and neural stem cell controls, and in embryonic and primary tumour explants, and that infection is influenced by activity of cholesterol biosynthesis pathways.
Collapse
Affiliation(s)
- Gemma Girdler
- Wellcome-MRC Stem Cell Institute, Dept of Clinical Neuroscience, Cambridge University, Cambridge, United Kingdom
| | - Tannia Gracia
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom
| | - Daniel Fountain
- Wellcome-MRC Stem Cell Institute, Department of Paediatrics, University of Cambridge, Cambridge, United Kingdom
- Salford Royal NHS Foundation Trust, Dept of Neurosurgery, Salford, United Kingdom
| | - Ted Fajardo Jr
- Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
| | - Jack Finlay
- Wellcome-MRC Stem Cell Institute, Department of Paediatrics, University of Cambridge, Cambridge, United Kingdom
| | - Clément Hallou
- Wellcome-MRC Stem Cell Institute, Department of Paediatrics, University of Cambridge, Cambridge, United Kingdom
| | - Steve Pollard
- MRC Centre for Regenerative Medicine and Edinburgh Cancer Research Centre, Edinburgh, United Kingdom
| | - Trevor Sweeney
- Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
| | - Fanni Gergely
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom
| | - David Rowitch
- Wellcome-MRC Stem Cell Institute, Department of Paediatrics, University of Cambridge, Cambridge, United Kingdom
| | - Harry Bulstrode
- Wellcome-MRC Stem Cell Institute, Dept of Clinical Neuroscience, Cambridge University, Cambridge, United Kingdom
| |
Collapse
|
12
|
Finlay J, Hallou C, Dewari P, Pollard S, Pathania M, Bulstrode H, Rowitch D. Characterising a SOX2+ OLIG2+ glioma stem cell using Crispr-engineered fluorescent reporters in primary patient-derived GBM and DIPG cells. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz167.039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Malignant glioma can be understood as a cancer stem cell disease. There is strong evidence that expression of a core set of neural stem cell master regulators is necessary and sufficient for tumour initiation in both adult and childhood disease subtypes, and across a range of underlying mutation signatures and expression profiles. We hypothesise that a double positive SOX2+ OLIG2+ progenitor is the cancer stem cell in H3K27M diffuse intrinsic pontine glioma (DIPG) and adult glioblastoma (GBM) alike. We present expression data in 4 patient-derived cell lines (2 adult GBM, 2 DIPG) in vitro and in a defined mutation mouse model of the H3K27M disease, demonstrating high expression levels of SOX2 and OLIG2 in serum-free culture and especially in the invasive tumour. We then demonstrate derivation of patient-derived human dual reporter lines, using a CRISPR targeting approach to add fluorescent reporters at the endogenous SOX2 and OLIG2 loci. With these tools, we aim to characterise the tumour-initiating potential of the SOX2+ OLIG2+ fraction. We further aim to identify cell surface markers whose expression is driven by this transcription program and which might represent targets for novel molecular therapies.
Collapse
Affiliation(s)
- Jack Finlay
- University of Cambridge, Cambridge, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
13
|
Tabet A, Mommer S, Vigil JA, Hallou C, Bulstrode H, Scherman OA. Mechanical Characterization of Human Brain Tissue and Soft Dynamic Gels Exhibiting Electromechanical Neuro-Mimicry. Adv Healthc Mater 2019; 8:e1900068. [PMID: 30945474 DOI: 10.1002/adhm.201900068] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2019] [Revised: 02/13/2019] [Indexed: 12/13/2022]
Abstract
Synthetic hydrogels are an important class of materials in tissue engineering, drug delivery, and other biomedical fields. Their mechanical and electrical properties can be tuned to match those of biological tissues. In this work, hydrogels that exhibit both mechanical and electrical biomimicry are reported. The presented dual networks consist of supramolecular networks formed from 2:1 homoternary complexes of imidazolium-based guest molecules in cucubit[8]uril and covalent networks of oligoethylene glycol-(di)methacrylate. The viscoelastic properties of human brain tissues are also investigated. The mechanical properties of the dual network gels are benchmarked against the human tissue, and it is found that they both are neuro-mimetic and exhibit cytocompatibility in a neural stem cell model.
Collapse
Affiliation(s)
- Anthony Tabet
- Melville Laboratory for Polymer SynthesisDepartment of ChemistryUniversity of Cambridge Lensfield Road Cambridge CB2 1EW UK
- Department of PaediatricsAddenbrooke's HospitalUniversity of Cambridge Hills Road Cambridge CB2 0QQ UK
| | - Stefan Mommer
- Melville Laboratory for Polymer SynthesisDepartment of ChemistryUniversity of Cambridge Lensfield Road Cambridge CB2 1EW UK
| | - Julian A. Vigil
- Melville Laboratory for Polymer SynthesisDepartment of ChemistryUniversity of Cambridge Lensfield Road Cambridge CB2 1EW UK
| | - Clement Hallou
- Department of PaediatricsAddenbrooke's HospitalUniversity of Cambridge Hills Road Cambridge CB2 0QQ UK
| | - Harry Bulstrode
- Department of PaediatricsAddenbrooke's HospitalUniversity of Cambridge Hills Road Cambridge CB2 0QQ UK
| | - Oren A. Scherman
- Melville Laboratory for Polymer SynthesisDepartment of ChemistryUniversity of Cambridge Lensfield Road Cambridge CB2 1EW UK
| |
Collapse
|
14
|
Haynes HR, Scott HL, Killick-Cole CL, Shaw G, Brend T, Hares KM, Redondo J, Kemp KC, Ballesteros LS, Herman A, Cordero-Llana O, Singleton WG, Mills F, Batstone T, Bulstrode H, Kauppinen RA, Wurdak H, Uney JB, Short SC, Wilkins A, Kurian KM. shRNA-mediated PPARα knockdown in human glioma stem cells reduces in vitro proliferation and inhibits orthotopic xenograft tumour growth. J Pathol 2018; 247:422-434. [PMID: 30565681 PMCID: PMC6462812 DOI: 10.1002/path.5201] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2018] [Revised: 10/18/2018] [Accepted: 11/13/2018] [Indexed: 12/12/2022]
Abstract
The overall survival for patients with primary glioblastoma is very poor. Glioblastoma contains a subpopulation of glioma stem cells (GSC) that are responsible for tumour initiation, treatment resistance and recurrence. PPARα is a transcription factor involved in the control of lipid, carbohydrate and amino acid metabolism. We have recently shown that PPARα gene and protein expression is increased in glioblastoma and has independent clinical prognostic significance in multivariate analyses. In this work, we report that PPARα is overexpressed in GSC compared to foetal neural stem cells. To investigate the role of PPARα in GSC, we knocked down its expression using lentiviral transduction with short hairpin RNA (shRNA). Transduced GSC were tagged with luciferase and stereotactically xenografted into the striatum of NOD-SCID mice. Bioluminescent and magnetic resonance imaging showed that knockdown (KD) of PPARα reduced the tumourigenicity of GSC in vivo. PPARα-expressing control GSC xenografts formed invasive histological phenocopies of human glioblastoma, whereas PPARα KD GSC xenografts failed to establish viable intracranial tumours. PPARα KD GSC showed significantly reduced proliferative capacity and clonogenic potential in vitro with an increase in cellular senescence. In addition, PPARα KD resulted in significant downregulation of the stem cell factors c-Myc, nestin and SOX2. This was accompanied by downregulation of the PPARα-target genes and key regulators of fatty acid oxygenation ACOX1 and CPT1A, with no compensatory increase in glycolytic flux. These data establish the aberrant overexpression of PPARα in GSC and demonstrate that this expression functions as an important regulator of tumourigenesis, linking self-renewal and the malignant phenotype in this aggressive cancer stem cell subpopulation. We conclude that targeting GSC PPARα expression may be a therapeutically beneficial strategy with translational potential as an adjuvant treatment. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
Collapse
Affiliation(s)
- Harry R Haynes
- Brain Tumour Research Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.,Department of Cellular Pathology, North Bristol NHS Trust, Bristol, UK
| | - Helen L Scott
- Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Clare L Killick-Cole
- Functional Neurosurgery Research Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Gary Shaw
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
| | - Tim Brend
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
| | - Kelly M Hares
- Multiple Sclerosis and Stem Cell Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Juliana Redondo
- Multiple Sclerosis and Stem Cell Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Kevin C Kemp
- Multiple Sclerosis and Stem Cell Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Lorena S Ballesteros
- Flow Cytometry Facility, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK
| | - Andrew Herman
- Flow Cytometry Facility, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK
| | - Oscar Cordero-Llana
- Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - William G Singleton
- Functional Neurosurgery Research Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.,Department of Neurosurgery, North Bristol NHS Trust, Bristol, UK
| | - Francesca Mills
- Department of Clinical Biochemistry, North Bristol NHS Trust, Bristol, UK
| | - Tom Batstone
- Bioinformatics Facility, School of Biological Sciences, University of Bristol, Bristol, UK
| | - Harry Bulstrode
- Department of Clinical Neuroscience and Stem Cell Institute, University of Cambridge, Cambridge, UK
| | - Risto A Kauppinen
- Clinical Research and Imaging Centre, University of Bristol, Bristol, UK
| | - Heiko Wurdak
- Stem Cells and Brain Tumour Group, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
| | - James B Uney
- Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Susan C Short
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
| | - Alastair Wilkins
- Multiple Sclerosis and Stem Cell Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Kathreena M Kurian
- Brain Tumour Research Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| |
Collapse
|
15
|
Durnford S, Bulstrode H, Durnford A, Chakraborty A, Tarmey N. Reply from authors to letter on Temporising an extradural haematoma by intraosseous needle craniostomy in the District General Hospital by non-neurosurgical doctors - a case report. J Intensive Care Soc 2018; 19:275. [PMID: 30159022 PMCID: PMC6110031 DOI: 10.1177/1751143717746049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/31/2024] Open
|
16
|
Fabelo H, Ortega S, Ravi D, Kiran BR, Sosa C, Bulters D, Callicó GM, Bulstrode H, Szolna A, Piñeiro JF, Kabwama S, Madroñal D, Lazcano R, J-O’Shanahan A, Bisshopp S, Hernández M, Báez A, Yang GZ, Stanciulescu B, Salvador R, Juárez E, Sarmiento R. Spatio-spectral classification of hyperspectral images for brain cancer detection during surgical operations. PLoS One 2018; 13:e0193721. [PMID: 29554126 PMCID: PMC5858847 DOI: 10.1371/journal.pone.0193721] [Citation(s) in RCA: 59] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2017] [Accepted: 02/06/2018] [Indexed: 11/18/2022] Open
Abstract
Surgery for brain cancer is a major problem in neurosurgery. The diffuse infiltration into the surrounding normal brain by these tumors makes their accurate identification by the naked eye difficult. Since surgery is the common treatment for brain cancer, an accurate radical resection of the tumor leads to improved survival rates for patients. However, the identification of the tumor boundaries during surgery is challenging. Hyperspectral imaging is a non-contact, non-ionizing and non-invasive technique suitable for medical diagnosis. This study presents the development of a novel classification method taking into account the spatial and spectral characteristics of the hyperspectral images to help neurosurgeons to accurately determine the tumor boundaries in surgical-time during the resection, avoiding excessive excision of normal tissue or unintentionally leaving residual tumor. The algorithm proposed in this study to approach an efficient solution consists of a hybrid framework that combines both supervised and unsupervised machine learning methods. Firstly, a supervised pixel-wise classification using a Support Vector Machine classifier is performed. The generated classification map is spatially homogenized using a one-band representation of the HS cube, employing the Fixed Reference t-Stochastic Neighbors Embedding dimensional reduction algorithm, and performing a K-Nearest Neighbors filtering. The information generated by the supervised stage is combined with a segmentation map obtained via unsupervised clustering employing a Hierarchical K-Means algorithm. The fusion is performed using a majority voting approach that associates each cluster with a certain class. To evaluate the proposed approach, five hyperspectral images of surface of the brain affected by glioblastoma tumor in vivo from five different patients have been used. The final classification maps obtained have been analyzed and validated by specialists. These preliminary results are promising, obtaining an accurate delineation of the tumor area.
Collapse
Affiliation(s)
- Himar Fabelo
- Institute for Applied Microelectronics (IUMA), University of Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain
- * E-mail:
| | - Samuel Ortega
- Institute for Applied Microelectronics (IUMA), University of Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain
| | - Daniele Ravi
- The Hamlyn Centre, Imperial College London (ICL), London, United Kingdom
| | - B. Ravi Kiran
- Laboratoire CRISTAL, Université Lille 3, Villeneuve-d’Ascq, France
| | - Coralia Sosa
- Department of Neurosurgery, University Hospital Doctor Negrin, Las Palmas de Gran Canaria, Spain
| | - Diederik Bulters
- Wessex Neurological Centre, University Hospital Southampton, Tremona Road, Southampton, United Kingdom
| | - Gustavo M. Callicó
- Institute for Applied Microelectronics (IUMA), University of Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain
| | - Harry Bulstrode
- Department of Neurosurgery, Addenbrookes Hospital, University of Cambridge, Cambridge, United Kingdom
| | - Adam Szolna
- Department of Neurosurgery, University Hospital Doctor Negrin, Las Palmas de Gran Canaria, Spain
| | - Juan F. Piñeiro
- Department of Neurosurgery, University Hospital Doctor Negrin, Las Palmas de Gran Canaria, Spain
| | - Silvester Kabwama
- Wessex Neurological Centre, University Hospital Southampton, Tremona Road, Southampton, United Kingdom
| | - Daniel Madroñal
- Centre of Software Technologies and Multimedia Systems (CITSEM), Universidad Politecnica de Madrid (UPM), Madrid, Spain
| | - Raquel Lazcano
- Centre of Software Technologies and Multimedia Systems (CITSEM), Universidad Politecnica de Madrid (UPM), Madrid, Spain
| | - Aruma J-O’Shanahan
- Department of Neurosurgery, University Hospital Doctor Negrin, Las Palmas de Gran Canaria, Spain
| | - Sara Bisshopp
- Department of Neurosurgery, University Hospital Doctor Negrin, Las Palmas de Gran Canaria, Spain
| | - María Hernández
- Department of Neurosurgery, University Hospital Doctor Negrin, Las Palmas de Gran Canaria, Spain
| | - Abelardo Báez
- Institute for Applied Microelectronics (IUMA), University of Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain
| | - Guang-Zhong Yang
- The Hamlyn Centre, Imperial College London (ICL), London, United Kingdom
| | - Bogdan Stanciulescu
- Ecole Nationale Supérieure des Mines de Paris (ENSMP), MINES ParisTech, Paris, France
| | - Rubén Salvador
- Centre of Software Technologies and Multimedia Systems (CITSEM), Universidad Politecnica de Madrid (UPM), Madrid, Spain
| | - Eduardo Juárez
- Centre of Software Technologies and Multimedia Systems (CITSEM), Universidad Politecnica de Madrid (UPM), Madrid, Spain
| | - Roberto Sarmiento
- Institute for Applied Microelectronics (IUMA), University of Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain
| |
Collapse
|
17
|
Durnford S, Bulstrode H, Durnford A, Chakraborty A, Tarmey NT. Temporising an extradural haematoma by intraosseous needle craniostomy in the District General Hospital by non-neurosurgical doctors - A case report. J Intensive Care Soc 2018; 19:76-79. [PMID: 29456607 PMCID: PMC5810882 DOI: 10.1177/1751143717734997] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
We report the case of a 69-year-old man admitted to the emergency department of a UK district general hospital with an extradural haematoma following closed head injury. He deteriorated rapidly before transfer to the regional neurosurgical centre and was treated with decompression of the extradural haematoma through an EZ-IO™ intraosseous needle in our department, with telephone guidance from the neurosurgeon. We believe this to be the first reported use of this technique in a district general hospital.
Collapse
Affiliation(s)
- Sahra Durnford
- Department of Critical Care, Queen Alexandra Hospital, Portsmouth, UK
| | - Harry Bulstrode
- Wessex Neurosurgical Centre, University Hospital Southampton, UK
| | - Andrew Durnford
- Wessex Neurosurgical Centre, University Hospital Southampton, UK
| | | | - Nicholas T Tarmey
- Department of Critical Care, Queen Alexandra Hospital, Portsmouth, UK
| |
Collapse
|
18
|
Bulstrode H, Kabwama S, Durnford A, Hempenstall J, Chakraborty A. Temporising extradural haematoma by craniostomy using an intraosseous needle. Injury 2017; 48:1098-1100. [PMID: 28238447 DOI: 10.1016/j.injury.2017.02.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/13/2016] [Revised: 02/11/2017] [Accepted: 02/17/2017] [Indexed: 02/02/2023]
Abstract
We report a novel application of intraosseous needle drainage, alleviating raised intracranial pressure due to extradural haematoma. The potential application of this technique in preventing secondary brain injury and herniation during transfer to a neurosurgical unit is discussed.
Collapse
Affiliation(s)
- Harry Bulstrode
- Department of Clinical Neurosciences, Addenbrookes Hospital, Cambridge CB2 0QQ, United Kingdom.
| | | | - Andrew Durnford
- Wessex Neurological Centre, Southampton General Hospital, SO16 6YD, United Kingdom.
| | - Jonathan Hempenstall
- Wessex Neurological Centre, Southampton General Hospital, SO16 6YD, United Kingdom.
| | - Aabir Chakraborty
- Wessex Neurological Centre, Southampton General Hospital, SO16 6YD, United Kingdom.
| |
Collapse
|
19
|
Bulstrode H, Johnstone E, Marques-Torrejon MA, Ferguson KM, Bressan RB, Blin C, Grant V, Gogolok S, Gangoso E, Gagrica S, Ender C, Fotaki V, Sproul D, Bertone P, Pollard SM. Elevated FOXG1 and SOX2 in glioblastoma enforces neural stem cell identity through transcriptional control of cell cycle and epigenetic regulators. Genes Dev 2017; 31:757-773. [PMID: 28465359 PMCID: PMC5435889 DOI: 10.1101/gad.293027.116] [Citation(s) in RCA: 79] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2016] [Accepted: 03/30/2017] [Indexed: 12/11/2022]
Abstract
Glioblastoma multiforme (GBM) is an aggressive brain tumor driven by cells with hallmarks of neural stem (NS) cells. GBM stem cells frequently express high levels of the transcription factors FOXG1 and SOX2. Here we show that increased expression of these factors restricts astrocyte differentiation and can trigger dedifferentiation to a proliferative NS cell state. Transcriptional targets include cell cycle and epigenetic regulators (e.g., Foxo3, Plk1, Mycn, Dnmt1, Dnmt3b, and Tet3). Foxo3 is a critical repressed downstream effector that is controlled via a conserved FOXG1/SOX2-bound cis-regulatory element. Foxo3 loss, combined with exposure to the DNA methylation inhibitor 5-azacytidine, enforces astrocyte dedifferentiation. DNA methylation profiling in differentiating astrocytes identifies changes at multiple polycomb targets, including the promoter of Foxo3 In patient-derived GBM stem cells, CRISPR/Cas9 deletion of FOXG1 does not impact proliferation in vitro; however, upon transplantation in vivo, FOXG1-null cells display increased astrocyte differentiation and up-regulate FOXO3. In contrast, SOX2 ablation attenuates proliferation, and mutant cells cannot be expanded in vitro. Thus, FOXG1 and SOX2 operate in complementary but distinct roles to fuel unconstrained self-renewal in GBM stem cells via transcriptional control of core cell cycle and epigenetic regulators.
Collapse
Affiliation(s)
- Harry Bulstrode
- Medical Research Council (MRC) Centre for Regenerative Medicine
- Edinburgh Cancer Research UK Cancer Centre, University of Edinburgh, Edinburgh EH16 4UU, United Kingdom
| | - Ewan Johnstone
- Wellcome Trust-MRC Stem Cell Institute, University of Cambridge, Cambridge CB2 1QR, United Kingdom
| | - Maria Angeles Marques-Torrejon
- Medical Research Council (MRC) Centre for Regenerative Medicine
- Edinburgh Cancer Research UK Cancer Centre, University of Edinburgh, Edinburgh EH16 4UU, United Kingdom
| | - Kirsty M Ferguson
- Medical Research Council (MRC) Centre for Regenerative Medicine
- Edinburgh Cancer Research UK Cancer Centre, University of Edinburgh, Edinburgh EH16 4UU, United Kingdom
| | - Raul Bardini Bressan
- Medical Research Council (MRC) Centre for Regenerative Medicine
- Edinburgh Cancer Research UK Cancer Centre, University of Edinburgh, Edinburgh EH16 4UU, United Kingdom
| | - Carla Blin
- Medical Research Council (MRC) Centre for Regenerative Medicine
- Edinburgh Cancer Research UK Cancer Centre, University of Edinburgh, Edinburgh EH16 4UU, United Kingdom
| | - Vivien Grant
- Medical Research Council (MRC) Centre for Regenerative Medicine
- Edinburgh Cancer Research UK Cancer Centre, University of Edinburgh, Edinburgh EH16 4UU, United Kingdom
| | - Sabine Gogolok
- Medical Research Council (MRC) Centre for Regenerative Medicine
- Edinburgh Cancer Research UK Cancer Centre, University of Edinburgh, Edinburgh EH16 4UU, United Kingdom
| | - Ester Gangoso
- Medical Research Council (MRC) Centre for Regenerative Medicine
- Edinburgh Cancer Research UK Cancer Centre, University of Edinburgh, Edinburgh EH16 4UU, United Kingdom
| | - Sladjana Gagrica
- Department of Cancer Biology, UCL Cancer Institute, University College London, London WC1E 6BT, United Kingdom
| | - Christine Ender
- Department of Cancer Biology, UCL Cancer Institute, University College London, London WC1E 6BT, United Kingdom
| | - Vassiliki Fotaki
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh EH8 9XD, United Kingdom
| | - Duncan Sproul
- MRC Human Genetics Unit
- Edinburgh Cancer Research Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, United Kingdom
| | - Paul Bertone
- Wellcome Trust-MRC Stem Cell Institute, University of Cambridge, Cambridge CB2 1QR, United Kingdom
| | - Steven M Pollard
- Medical Research Council (MRC) Centre for Regenerative Medicine
- Edinburgh Cancer Research UK Cancer Centre, University of Edinburgh, Edinburgh EH16 4UU, United Kingdom
| |
Collapse
|
20
|
Bressan RB, Dewari PS, Kalantzaki M, Gangoso E, Matjusaitis M, Garcia-Diaz C, Blin C, Grant V, Bulstrode H, Gogolok S, Skarnes WC, Pollard SM. Efficient CRISPR/Cas9-assisted gene targeting enables rapid and precise genetic manipulation of mammalian neural stem cells. Development 2017; 144:635-648. [PMID: 28096221 PMCID: PMC5312033 DOI: 10.1242/dev.140855] [Citation(s) in RCA: 74] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2016] [Accepted: 12/15/2016] [Indexed: 01/09/2023]
Abstract
Mammalian neural stem cell (NSC) lines provide a tractable model for discovery across stem cell and developmental biology, regenerative medicine and neuroscience. They can be derived from foetal or adult germinal tissues and continuously propagated in vitro as adherent monolayers. NSCs are clonally expandable, genetically stable, and easily transfectable - experimental attributes compatible with targeted genetic manipulations. However, gene targeting, which is crucial for functional studies of embryonic stem cells, has not been exploited to date in NSC lines. Here, we deploy CRISPR/Cas9 technology to demonstrate a variety of sophisticated genetic modifications via gene targeting in both mouse and human NSC lines, including: (1) efficient targeted transgene insertion at safe harbour loci (Rosa26 and AAVS1); (2) biallelic knockout of neurodevelopmental transcription factor genes; (3) simple knock-in of epitope tags and fluorescent reporters (e.g. Sox2-V5 and Sox2-mCherry); and (4) engineering of glioma mutations (TP53 deletion; H3F3A point mutations). These resources and optimised methods enable facile and scalable genome editing in mammalian NSCs, providing significant new opportunities for functional genetic analysis.
Collapse
Affiliation(s)
| | - Pooran Singh Dewari
- MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK
| | - Maria Kalantzaki
- MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK
| | - Ester Gangoso
- MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK
| | - Mantas Matjusaitis
- MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK
| | - Claudia Garcia-Diaz
- MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK
| | - Carla Blin
- MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK
| | - Vivien Grant
- MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK
| | - Harry Bulstrode
- MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK
| | - Sabine Gogolok
- MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK
| | - William C Skarnes
- Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, UK
| | - Steven M Pollard
- MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
21
|
Siney EJ, Holden A, Casselden E, Bulstrode H, Thomas GJ, Willaime-Morawek S. Metalloproteinases ADAM10 and ADAM17 Mediate Migration and Differentiation in Glioblastoma Sphere-Forming Cells. Mol Neurobiol 2016; 54:3893-3905. [PMID: 27541285 PMCID: PMC5443867 DOI: 10.1007/s12035-016-0053-6] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2015] [Accepted: 08/09/2016] [Indexed: 01/03/2023]
Abstract
Glioblastoma is the most common form of primary malignant brain tumour. These tumours are highly proliferative and infiltrative resulting in a median patient survival of only 14 months from diagnosis. The current treatment regimens are ineffective against the small population of cancer stem cells residing in the tumourigenic niche; however, a new therapeutic approach could involve the removal of these cells from the microenvironment that maintains the cancer stem cell phenotype. We have isolated multipotent sphere-forming cells from human high grade glioma (glioma sphere-forming cells (GSCs)) to investigate the adhesive and migratory properties of these cells in vitro. We have focused on the role of two closely related metalloproteinases ADAM10 and ADAM17 due to their high expression in glioblastoma and GSCs and their ability to activate cytokines and growth factors. Here, we report that ADAM10 and ADAM17 inhibition selectively increases GSC, but not neural stem cell, migration and that the migrated GSCs exhibit a differentiated phenotype. We also observed a correlation between nestin, a stem/progenitor marker, and fibronectin, an extracellular matrix protein, expression in high grade glioma tissues. GSCs adherence on fibronectin is mediated by α5β1 integrin, where fibronectin further promotes GSC migration and is an effective candidate for in vivo cancer stem cell migration out of the tumourigenic niche. Our results suggest that therapies against ADAM10 and ADAM17 may promote cancer stem cell migration away from the tumourigenic niche resulting in a differentiated phenotype that is more susceptible to treatment.
Collapse
Affiliation(s)
- Elodie J Siney
- Clinical Neurosciences, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK. .,Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK. .,Southampton General Hospital, LF51, South Laboratory Block, Southampton, SO16 6YD, UK.
| | - Alexander Holden
- Clinical Neurosciences, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK
| | - Elizabeth Casselden
- Clinical Neurosciences, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK
| | - Harry Bulstrode
- Wessex Neurological Centre, University Hospital Southampton, Southampton, SO16 6YD, UK
| | - Gareth J Thomas
- Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK
| | | |
Collapse
|
22
|
Carén H, Stricker SH, Bulstrode H, Gagrica S, Johnstone E, Bartlett TE, Feber A, Wilson G, Teschendorff AE, Bertone P, Beck S, Pollard SM. Glioblastoma Stem Cells Respond to Differentiation Cues but Fail to Undergo Commitment and Terminal Cell-Cycle Arrest. Stem Cell Reports 2015; 5:829-842. [PMID: 26607953 PMCID: PMC4649264 DOI: 10.1016/j.stemcr.2015.09.014] [Citation(s) in RCA: 79] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2015] [Revised: 09/16/2015] [Accepted: 09/16/2015] [Indexed: 12/29/2022] Open
Abstract
Glioblastoma (GBM) is an aggressive brain tumor whose growth is driven by stemcell-like cells. BMP signaling triggers cell-cycle exit and differentiation of GBM stemcells (GSCs) and, therefore, might have therapeutic value. However, the epigenetic mechanisms that accompany differentiation remain poorly defined. It is also unclear whether cell-cycle arrest is terminal. Herewe find only a subset ofGSCcultures exhibit astrocyte differentiation in response to BMP. Although overtly differentiated non-cycling astrocytes are generated, they remain vulnerable to cell-cycle re-entry and fail to appropriately reconfigure DNA methylation patterns. Chromatin accessibility mapping identified loci that failed to alter in response to BMP and these were enriched in SOX transcription factor-binding motifs. SOX transcription factors, therefore, may limit differentiation commitment. A similar propensity for cell-cycle re-entry and de-differentiation was observed in GSC-derived oligodendrocyte-like cells. These findings highlight significant obstacles to BMP-induced differentiation as therapy forGBM.
Collapse
Affiliation(s)
- Helena Carén
- Department of Cancer Biology, UCL Cancer Institute, University College London, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK; Sahlgrenska Cancer Center, Department of Pathology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden; Samantha Dickson Brain Cancer Unit, University College London, London WC1E 6BT, UK
| | - Stefan H Stricker
- Department of Cancer Biology, UCL Cancer Institute, University College London, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK; Samantha Dickson Brain Cancer Unit, University College London, London WC1E 6BT, UK
| | - Harry Bulstrode
- Genome Biology and Developmental Biology Units, European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, 69117 Heidelberg, Germany
| | - Sladjana Gagrica
- Department of Cancer Biology, UCL Cancer Institute, University College London, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK
| | - Ewan Johnstone
- European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Trust Genome Campus, Cambridge CB10 1SD, UK
| | - Thomas E Bartlett
- Department of Mathematics and CoMPLEX, University College London, London WC1E 6BT, UK
| | - Andrew Feber
- Department of Cancer Biology, UCL Cancer Institute, University College London, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK
| | - Gareth Wilson
- Department of Cancer Biology, UCL Cancer Institute, University College London, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK
| | - Andrew E Teschendorff
- Department of Cancer Biology, UCL Cancer Institute, University College London, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK
| | - Paul Bertone
- Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Tennis Court Road, University of Cambridge, Cambridge CB2 1QR, UK; European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Trust Genome Campus, Cambridge CB10 1SD, UK; Genome Biology and Developmental Biology Units, European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, 69117 Heidelberg, Germany
| | - Stephan Beck
- Department of Cancer Biology, UCL Cancer Institute, University College London, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK.
| | - Steven M Pollard
- Department of Cancer Biology, UCL Cancer Institute, University College London, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK; Samantha Dickson Brain Cancer Unit, University College London, London WC1E 6BT, UK; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh bioQuarter, 5 Little France Drive, Edinburgh EH16 4UU, UK.
| |
Collapse
|
23
|
Stewart SK, Morris TJ, Guilhamon P, Bulstrode H, Bachman M, Balasubramanian S, Beck S. oxBS-450K: a method for analysing hydroxymethylation using 450K BeadChips. Methods 2015; 72:9-15. [PMID: 25175075 PMCID: PMC4304834 DOI: 10.1016/j.ymeth.2014.08.009] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2014] [Revised: 08/07/2014] [Accepted: 08/15/2014] [Indexed: 12/14/2022] Open
Abstract
DNA methylation analysis has become an integral part of biomedical research. For high-throughput applications such as epigenome-wide association studies, the Infinium HumanMethylation450 (450K) BeadChip is currently the platform of choice. However, BeadChip processing relies on traditional bisulfite (BS) based protocols which cannot discriminate between 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC). Here, we report the adaptation of the recently developed oxidative bisulfite (oxBS) chemistry to specifically detect both 5mC and 5hmC in a single workflow using 450K BeadChips, termed oxBS-450K. Supported by validation using mass spectrometry and pyrosequencing, we demonstrate reproducible (R(2)>0.99) detection of 5hmC in human brain tissue using the optimised oxBS-450K protocol described here.
Collapse
Affiliation(s)
- Sabrina K Stewart
- Department of Cancer Biology, UCL Cancer Institute, University College London, London WC1E 6BT, UK
| | - Tiffany J Morris
- Department of Cancer Biology, UCL Cancer Institute, University College London, London WC1E 6BT, UK
| | - Paul Guilhamon
- Department of Cancer Biology, UCL Cancer Institute, University College London, London WC1E 6BT, UK
| | - Harry Bulstrode
- Scottish Centre for Regenerative Medicine, Edinburgh EH16 4UU, UK
| | - Martin Bachman
- Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK
| | | | - Stephan Beck
- Department of Cancer Biology, UCL Cancer Institute, University College London, London WC1E 6BT, UK.
| |
Collapse
|
24
|
Bulstrode H, Pollard S. O05 * FOXG1 IS A CANDIDATE TRANSCRIPTIONAL MASTER REGULATOR IN NEURAL STEM CELLS AND GLIOBLASTOMA. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou250.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Bulstrode H, Nicoll JAR, Hudson G, Chinnery PF, Di Pietro V, Belli A. Mitochondrial DNA and traumatic brain injury. Ann Neurol 2014; 75:186-95. [PMID: 24523223 PMCID: PMC4112718 DOI: 10.1002/ana.24116] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2013] [Revised: 02/04/2014] [Accepted: 02/04/2014] [Indexed: 01/08/2023]
Abstract
Objective Traumatic brain injury (TBI) is a multifactorial pathology with great interindividual variability in response to injury and outcome. Mitochondria contain their own DNA (mtDNA) with genomic variants that have different physiological and pathological characteristics, including susceptibility to neurodegeneration. Given the central role of mitochondria in the pathophysiology of neurological injury, we hypothesized that its genomic variants may account for the variability in outcome following TBI. Methods We undertook an analysis of mitochondrial haplogroups in a large, well‐characterized cohort of 1,094 TBI patients. A proportional odds model including age, brain computed tomography characteristics, injury severity, pupillary reactivity, mitochondrial haplogroups, and APOE was applied to Glasgow Outcome Score (GOS) data. Results mtDNA had a significant association with 6‐month GOS (p = 0.008). Haplogroup K was significantly associated with favorable outcome (odds ratio = 1.64, 95% confidence interval = 1.08–2.51, p = 0.02). There was also a significant interaction between mitochondrial genome and age (p = 0.002), with a strong protective effect of both haplogroups T (p = 0.015) and K (p = 0.017) with advancing age. We also found a strong interaction between APOE and mitochondrial haplogroups (p = 0.001), indicating a protective effect of haplogroup K in carriers of the APOE ε4 allele. Interpretation These findings reveal an interplay between mitochondrial DNA, pathophysiology of TBI, and aging. Haplogroups K and T, which share a common maternal ancestor, are shown as protective in TBI. The data also suggest that the APOE pathways interact with genetically regulated mitochondrial functions in the response to acute injury, as previously reported in Alzheimer disease. Ann Neurol 2014;75:186–195
Collapse
|
26
|
Bulstrode H, Ditchfield A, Nicoll J, Shenouda E. Pilocytic astrocytoma originating at the cavernous sinus. Acta Neurochir (Wien) 2012; 154:291-3. [PMID: 21892636 DOI: 10.1007/s00701-011-1138-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2011] [Accepted: 08/19/2011] [Indexed: 11/24/2022]
Abstract
We report a case of histologically proven pilocytic astrocytoma arising within the cavernous sinus, confirmed radiographically and at operation. We discuss the implications in the context of previous reports of ectopic glioma origin. In particular, the possiblity of glioma development within glial cell islands in the peripheral segment of cranial nerves is explored.
Collapse
Affiliation(s)
- Harry Bulstrode
- Wessex Neurological Centre, Southampton General Hospital, Southampton, UK.
| | | | | | | |
Collapse
|
27
|
Hunt V, Bulstrode C, Baldwin P, Bulstrode H, Mansfield C. Training teachers--changing practice? J R Coll Surg Edinb 2002; 47:619-22. [PMID: 12363187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
Abstract
A three-day course was designed to improve the skills of those who provide clinical training to medical students. This long-term follow up of past participants shows a sustained improvement to their skills, especially in terms of involving students in their own learning, and giving them positive feedback.
Collapse
Affiliation(s)
- V Hunt
- John Radcliffe Hospital, Oxford, UK
| | | | | | | | | |
Collapse
|